Summary
1.4500 -0.0800(-5.2729%)05/17/2024
TRACON Pharmaceuticals Inc (TCON)
TRACON Pharmaceuticals Inc (TCON)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.1050 | 5.2941 | 832.2917 | 817.9487 | 1,093.3333 | 146.8285 | -74.0580 | -98.0957 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.7900 | |
| Open | 1.8300 | |
| High | 1.8400 | |
| Low | 1.7400 | |
| Volume | 88,795 | |
| Change | -0.0200 | |
| Change % | -1.1050 | |
| Avg Volume (20 Days) | 278,726 | |
| Volume/Avg Volume (20 Days) Ratio | 0.32 | |
| 52 Week Range | 0.13 - 3.37 | |
| Price vs 52 Week High | -46.88% | |
| Price vs 52 Week Low | 1,326.29% | |
| Range | -2.1858 | |
| Gap Up/Down | -0.0899 | |
Fundamentals | ||
| Market Capitalization (Mln) | 4 | |
| EBIDTA | -6,884,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 37.5000 | |
| Book Value | -0.3650 | |
| Earnings Per Share | -2.2000 | |
| EPS Estimate Current Quarter | -0.0800 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | -4.6200 | |
| EPS Estimate Next Year | -3.4300 | |
| Diluted EPS (TTM) | -2.2000 | |
| Revenues | ||
| Profit Marging | -0.2979 | |
| Operating Marging (TTM) | 0.1337 | |
| Return on asset (TTM) | -0.2916 | |
| Return on equity (TTM) | -12.7701 | |
| Revenue TTM | 12,045,000 | |
| Revenue per share TTM | 7.3570 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -13,888,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 11.8258 | |
| Revenue Enterprise Value | 0.0339 | |
| EBITDA Enterprise Value | -0.7889 | |
| Shares | ||
| Shares Outstanding | 2,275,220 | |
| Shares Float | 2,082,468 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 2.60 | |
| Institutions (%) | 11.66 | |
05/14 20:48 EST - seekingalpha.com
TRACON Pharmaceuticals, Inc. (TCON) Q1 2024 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Charles Theuer - President & CEO Scott Brown - CFO Conference Call Participants Matthew Venezia - Alliance Global Partners Operator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals First Quarter 2024 Earnings Conference Call. At this time, all callers are in a listen-only mode.
TRACON Pharmaceuticals, Inc. (TCON) Q1 2024 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Charles Theuer - President & CEO Scott Brown - CFO Conference Call Participants Matthew Venezia - Alliance Global Partners Operator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals First Quarter 2024 Earnings Conference Call. At this time, all callers are in a listen-only mode.
05/14 16:01 EST - globenewswire.com
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2024. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2024. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.
05/07 16:01 EST - globenewswire.com
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Tuesday, May 14, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Tuesday, May 14, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
04/10 06:30 EST - investorplace.com
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
Now could be a great time for investors to consider stacking up on penny stocks. These companies often have significant growth potential.
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
Now could be a great time for investors to consider stacking up on penny stocks. These companies often have significant growth potential.
04/08 09:10 EST - globenewswire.com
TRACON Pharmaceuticals Announces Reverse Stock Split
SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that, following stockholder approval at the special meeting of stockholders held on September 6, 2023 of a proposal authorizing the board of directors of the Company (the Board) to amend the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's outstanding common stock at a ratio in the range of one-for-five to one-for-twenty, the Company's Board today approved a reverse stock split of the Company's common stock at a ratio of one-for-twenty.
TRACON Pharmaceuticals Announces Reverse Stock Split
SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that, following stockholder approval at the special meeting of stockholders held on September 6, 2023 of a proposal authorizing the board of directors of the Company (the Board) to amend the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's outstanding common stock at a ratio in the range of one-for-five to one-for-twenty, the Company's Board today approved a reverse stock split of the Company's common stock at a ratio of one-for-twenty.
03/05 22:37 EST - seekingalpha.com
TRACON Pharmaceuticals, Inc. (TCON) Q4 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (TCON) Q4 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (TCON) Q4 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (TCON) Q4 2023 Earnings Call Transcript
03/05 16:02 EST - globenewswire.com
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.
02/28 16:02 EST - globenewswire.com
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2023 financial and operating results after the close of U.S. financial markets on Tuesday, March 5, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2023 financial and operating results after the close of U.S. financial markets on Tuesday, March 5, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
12/20 08:00 EST - globenewswire.com
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
Objective Response Rate by investigator review increased to 15% since interim analysis in September Full ENVASARC enrollment expected in 1Q 2024 and final data anticipated during 3Q 2024 SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that the ongoing pivotal Phase 2 ENVASARC trial has enrolled more than 70 of the 80 planned patients in Cohort C of single agent envafolimab treatment at a dose of 600 mg subQ every three weeks. Additional safety and efficacy data were reviewed for 46 patients enrolled into cohort C who were the subject of the September independent data monitoring committee (IDMC) review.
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
Objective Response Rate by investigator review increased to 15% since interim analysis in September Full ENVASARC enrollment expected in 1Q 2024 and final data anticipated during 3Q 2024 SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that the ongoing pivotal Phase 2 ENVASARC trial has enrolled more than 70 of the 80 planned patients in Cohort C of single agent envafolimab treatment at a dose of 600 mg subQ every three weeks. Additional safety and efficacy data were reviewed for 46 patients enrolled into cohort C who were the subject of the September independent data monitoring committee (IDMC) review.
11/21 07:55 EST - investorplace.com
Why Is Tracon Pharmaceuticals (TCON) Stock Up 19% Today?
Tracon Pharmaceuticals (NASDAQ: TCON ) stock is rocketing higher on Tuesday as investors react to a licensing agreement for its product development platform ( PDP ). According to a press release from the company, it has licensed this to a clinical-stage biotech company for an upfront payment of $3 million.
Why Is Tracon Pharmaceuticals (TCON) Stock Up 19% Today?
Tracon Pharmaceuticals (NASDAQ: TCON ) stock is rocketing higher on Tuesday as investors react to a licensing agreement for its product development platform ( PDP ). According to a press release from the company, it has licensed this to a clinical-stage biotech company for an upfront payment of $3 million.
11/20 08:00 EST - globenewswire.com
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment
SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced it has licensed its proprietary PDP of CRO-independent clinical research to a clinical stage biotech company for a $3.0 million upfront payment.
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment
SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced it has licensed its proprietary PDP of CRO-independent clinical research to a clinical stage biotech company for a $3.0 million upfront payment.
11/13 09:29 EST - investorplace.com
Why Is Tracon Pharmaceuticals (TCON) Stock Down 22% Today?
Tracon Pharmaceuticals (NASDAQ: TCON ) stock is falling on Monday as the company's shares retreat from a massive rally on Friday. That rally saw shares of TCON stock climb 43.9% higher during normal trading hours.
Why Is Tracon Pharmaceuticals (TCON) Stock Down 22% Today?
Tracon Pharmaceuticals (NASDAQ: TCON ) stock is falling on Monday as the company's shares retreat from a massive rally on Friday. That rally saw shares of TCON stock climb 43.9% higher during normal trading hours.
11/10 07:45 EST - investorplace.com
Why Is Tracon Pharmaceuticals (TCON) Stock Up 130% Today?
Tracon Pharmaceuticals (NASDAQ: TCON ) stock is rocketing higher on Friday after the biopharmaceutical company announced results for the third quarter of 2023. Tracon Pharmaceuticals starts its report with adjusted earnings per share of 29 cents.
Why Is Tracon Pharmaceuticals (TCON) Stock Up 130% Today?
Tracon Pharmaceuticals (NASDAQ: TCON ) stock is rocketing higher on Friday after the biopharmaceutical company announced results for the third quarter of 2023. Tracon Pharmaceuticals starts its report with adjusted earnings per share of 29 cents.
11/09 21:10 EST - seekingalpha.com
TRACON Pharmaceuticals, Inc. (TCON) Q3 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants Dr. Charles Theuer - President and CEO Scott Brown - CFO Conference Call Participants Ed White - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Third Quarter 2023 Earnings Conference Call.
TRACON Pharmaceuticals, Inc. (TCON) Q3 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants Dr. Charles Theuer - President and CEO Scott Brown - CFO Conference Call Participants Ed White - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Third Quarter 2023 Earnings Conference Call.
11/09 16:02 EST - globenewswire.com
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the third quarter ended September 30, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the third quarter ended September 30, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.
10/31 16:02 EST - globenewswire.com
TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023
SAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its third quarter 2023 financial and operating results after the close of U.S. financial markets on Thursday, November 9, 2023. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023
SAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its third quarter 2023 financial and operating results after the close of U.S. financial markets on Thursday, November 9, 2023. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
09/18 08:00 EST - globenewswire.com
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
Full ENVASARC accrual expected in Q4 and final data expected in mid-2024 Full ENVASARC accrual expected in Q4 and final data expected in mid-2024
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
Full ENVASARC accrual expected in Q4 and final data expected in mid-2024 Full ENVASARC accrual expected in Q4 and final data expected in mid-2024
09/05 16:02 EST - globenewswire.com
TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate at the following upcoming investor conferences and provide a company overview:
TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate at the following upcoming investor conferences and provide a company overview:
08/25 07:20 EST - investorplace.com
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product.
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product.
08/14 18:50 EST - seekingalpha.com
TRACON Pharmaceuticals, Inc. (TCON) Q2 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q2 2023 Earnings Call August 14, 2023 4:30 PM ET Company Participants Charles P. Theuer - President and CEO Scott B.
TRACON Pharmaceuticals, Inc. (TCON) Q2 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q2 2023 Earnings Call August 14, 2023 4:30 PM ET Company Participants Charles P. Theuer - President and CEO Scott B.